Ellen S. Baron

Boston, Massachusetts, United States Contact Info
2K followers 500+ connections

Join to view profile

About

Excellent fund raising and investment, negotiation and leadership skills. Strong social…

Activity

Join now to see all activity

Experience & Education

  • Outcome Capital

View Ellen S.’s full experience

See their title, tenure and more.

or

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Licenses & Certifications

  • FINRA Investment Banking Registration Graphic

    FINRA Investment Banking Registration

    FINRA

    Credential ID Series 79
  • FINRA Investment Banking Registration Graphic

    FINRA Investment Banking Registration

    FINRA

    Credential ID Series 63

Publications

  • Immuno-Oncology: Unicorns, China And The Perfect Storm

    In Vivo

    There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets. Unicorn transactions have emerged in the IO sector, as well as never seen before partnerships, financing deals that regularly hit above $200 million, and multibillion-dollar acquisitions and IPO valuations. The market is optimizing…

    There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets. Unicorn transactions have emerged in the IO sector, as well as never seen before partnerships, financing deals that regularly hit above $200 million, and multibillion-dollar acquisitions and IPO valuations. The market is optimizing multiple paths to liquidity at all stages of development and experiencing a shortening in time to exit, which is further propelling investor appetite.

    So what? As IO drugs demonstrate robust clinical potential and early movers reap market rewards, the segment continues to attract significant interest from the investor community as well as pharma and biotech players, triggering highly competitive behavior and intense transactional activity. IO may be the perfect storm for venture returns. It represents a radical change from traditional cytotoxic drugs, the capital markets are booming, and traditionally slow regulators have catalyzed meaningful new product approvals based on unprecedented clinical data. This is driving VCs flush with cash to engorge new IO market entrants with capital to hit value-inflecting milestones. Coupled with large players jumping at early M&As, biotech companies are enjoying a high probability to exit early.

    The question that remains: are we in the midst of a transformational inflection point in scientific progress leading to meaningful improvements in clinical outcomes or are we witnessing irrational exuberance by investors and strategic players leading to unduly escalated asset values? Time will tell.

Languages

  • French

    -

More activity by Ellen S.

View Ellen S.’s full profile

  • See who you know in common
  • Get introduced
  • Contact Ellen S. directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Add new skills with these courses

See all courses